AR131380A1 - Purinas 2,6,9-trisustituidas - Google Patents
Purinas 2,6,9-trisustituidasInfo
- Publication number
- AR131380A1 AR131380A1 ARP230103410A ARP230103410A AR131380A1 AR 131380 A1 AR131380 A1 AR 131380A1 AR P230103410 A ARP230103410 A AR P230103410A AR P230103410 A ARP230103410 A AR P230103410A AR 131380 A1 AR131380 A1 AR 131380A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- salts
- trisubstituted purines
- trisubstituted
- purines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos que tienen la estructura de fórmula (1) y sales farmacéuticamente aceptables de la misma, en donde R¹, R², R³, R⁴, y R⁵ son como se define en la especificación; composiciones farmacéuticas que comprenden estos compuestos y sales; uso de estos compuestos y sales para tratar o prevenir condiciones mediadas por cinasa 2 dependiente de ciclina (CDK2); kits que comprenden estos compuestos y sales; y métodos para fabricar estos compuestos y sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263387734P | 2022-12-16 | 2022-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131380A1 true AR131380A1 (es) | 2025-03-12 |
Family
ID=89473830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230103410A AR131380A1 (es) | 2022-12-16 | 2023-12-15 | Purinas 2,6,9-trisustituidas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20240247001A1 (es) |
| EP (1) | EP4634186A1 (es) |
| JP (1) | JP2026500305A (es) |
| KR (1) | KR20250121114A (es) |
| CN (1) | CN120359223A (es) |
| AR (1) | AR131380A1 (es) |
| AU (1) | AU2023393410A1 (es) |
| CL (1) | CL2025001706A1 (es) |
| CO (1) | CO2025009649A2 (es) |
| CR (1) | CR20250283A (es) |
| DO (1) | DOP2025000143A (es) |
| IL (1) | IL321433A (es) |
| MX (1) | MX2025006884A (es) |
| PE (1) | PE20251925A1 (es) |
| TW (1) | TWI922868B (es) |
| UY (1) | UY40564A (es) |
| WO (1) | WO2024127350A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202991A1 (en) * | 2024-03-29 | 2025-10-02 | Astrazeneca Ab | Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide |
| WO2026012471A1 (zh) * | 2024-07-11 | 2026-01-15 | 上海先声再明医药生物科技有限公司 | 取代嘌呤类化合物及其应用 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| CN119462661A (zh) * | 2024-09-24 | 2025-02-18 | 烟台皓元生物医药科技有限公司 | 一种azd-8421及其中间体的制备方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432164A (en) | 1991-10-24 | 1995-07-11 | Novo Nordisk A/S | C2,N6 -disubstituted adenosine derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| WO1997033591A1 (en) | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| AU2022497A (en) | 1996-03-13 | 1997-10-01 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| IL144675A0 (en) | 1999-02-01 | 2002-05-23 | Cv Therapeutics Inc | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α |
| GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| FR2793794B1 (fr) | 1999-05-21 | 2001-07-27 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| EP1377579B1 (en) | 2000-10-31 | 2009-03-25 | Aventis Pharmaceuticals Inc. | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| CA2463563A1 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| AU2002334992B2 (en) | 2001-10-12 | 2009-07-02 | Irm Llc | Methods for the synthesis of substituted purines |
| JP2005535631A (ja) | 2002-06-27 | 2005-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | プリン誘導体の合成 |
| WO2004069185A2 (en) | 2003-02-03 | 2004-08-19 | Cv Therapeutics Inc. | Partial and full agonists of a1 adenosine receptors |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| JP2007502776A (ja) | 2003-08-15 | 2007-02-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Rtk阻害剤としての6−置換アニリノプリン類 |
| MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
| JP2006056879A (ja) | 2004-07-21 | 2006-03-02 | Kobe Univ | インスリン抵抗性の改善剤、及びそのスクリーニング方法 |
| US7514417B2 (en) | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| BRPI0614502A2 (pt) | 2005-07-30 | 2011-03-29 | Astrazeneca Ab | Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto |
| WO2007028022A2 (en) | 2005-09-01 | 2007-03-08 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
| GB0606283D0 (en) | 2006-03-29 | 2006-05-10 | Cyclacel Ltd | Process |
| GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| CA2676138A1 (en) | 2007-01-26 | 2008-08-07 | Irm Llc | Compounds and compositions as kinase inhibitors |
| GB0706632D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | New purine derivatives |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| WO2009129094A2 (en) | 2008-04-15 | 2009-10-22 | Mallinckrodt Inc. | Compositions containing antiviral compounds and methods of using the same |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| US8377639B2 (en) | 2009-06-26 | 2013-02-19 | University Of Massachusetts | Compounds for modulating RNA binding proteins and uses therefor |
| US20130137728A1 (en) | 2010-03-24 | 2013-05-30 | MUSC Foundation for Research and Development | Compositions and Methods for the Treatment of Degenerative Diseases |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤 |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| DK2753605T3 (da) | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler |
| US9187480B2 (en) | 2012-02-17 | 2015-11-17 | Research Triangle Institute | Peripherally restricted diphenyl purine derivatives |
| RU2661896C2 (ru) | 2012-11-16 | 2018-07-23 | Мерк Шарп И Доум Корп. | Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека |
| US20140275178A1 (en) | 2013-03-13 | 2014-09-18 | Musc Foundation For Research Development | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| US9796714B2 (en) | 2013-05-20 | 2017-10-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Calcium channel agonists |
| WO2016011394A1 (en) | 2014-07-18 | 2016-01-21 | The General Hospital Corporation | Imaging agents for neural flux |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US20180000814A1 (en) | 2016-06-14 | 2018-01-04 | Joseph Hacia | Compositions and methods for the treatment of zellweger spectrum disorder |
| WO2018036414A1 (zh) | 2016-08-23 | 2018-03-01 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
| KR101893879B1 (ko) | 2017-03-31 | 2018-09-03 | 한국화학연구원 | 신규한 cdk 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 cdk 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US20190029977A1 (en) | 2017-04-24 | 2019-01-31 | Mercaptor Discoveries, Inc. | Use of Thiol Compounds to Treat Neurological Disease |
| CN110582496A (zh) | 2017-05-03 | 2019-12-17 | 格勒诺布尔-阿尔卑斯大学 | 用于合成多样取代的嘌呤的方法 |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| JP2022506682A (ja) | 2018-11-05 | 2022-01-17 | アビスタ ファーマ ソリューションズ,インコーポレーテッド | 化合物 |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤 |
| CA3128155C (en) | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| CN113692276B (zh) | 2019-02-19 | 2026-02-27 | 加利福尼亚大学董事会 | Nurr1受体调节剂 |
| WO2020181050A1 (en) | 2019-03-05 | 2020-09-10 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN111825674A (zh) | 2019-04-22 | 2020-10-27 | 上海仕谱生物科技有限公司 | 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 |
| CN114025758B (zh) | 2019-07-01 | 2026-05-08 | 钱立刚 | P2x7r拮抗剂 |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CN113024563B (zh) | 2019-12-24 | 2023-01-03 | 药康众拓(江苏)医药科技有限公司 | 嘧啶并五元杂环类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途 |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
| US12653888B2 (en) | 2020-05-04 | 2026-06-16 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for inducing immune responses to infectious agents |
| JP7853532B2 (ja) | 2020-05-19 | 2026-04-30 | ファーマコスモス ホールディング エー/エス | 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物 |
| US20260167619A2 (en) | 2020-09-22 | 2026-06-18 | Beone Medicines I Gmbh | Indoline compounds and derivatives as egfr inhibitors |
| CN122562781A (zh) | 2020-10-07 | 2026-08-14 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| EP4284415A4 (en) | 2021-01-26 | 2024-12-11 | Sigilon Therapeutics, Inc. | BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS |
| CN116981473A (zh) | 2021-01-26 | 2023-10-31 | 西吉隆医疗股份有限公司 | 用于治疗免疫介导的炎性疾病的组合物、装置和方法 |
| US20240374507A1 (en) | 2021-01-26 | 2024-11-14 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for inducing antigen-specific immune tolerance |
| WO2022266190A1 (en) | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
| CN117897384A (zh) | 2021-06-28 | 2024-04-16 | 缆图药品公司 | Cdk2抑制剂 |
| CN116813621A (zh) | 2023-06-08 | 2023-09-29 | 江南大学 | 9h嘌呤类化合物及其药物组合物和用途 |
-
2023
- 2023-12-15 AR ARP230103410A patent/AR131380A1/es unknown
- 2023-12-15 WO PCT/IB2023/062789 patent/WO2024127350A1/en not_active Ceased
- 2023-12-15 JP JP2025534800A patent/JP2026500305A/ja active Pending
- 2023-12-15 CR CR20250283A patent/CR20250283A/es unknown
- 2023-12-15 UY UY0001040564A patent/UY40564A/es unknown
- 2023-12-15 AU AU2023393410A patent/AU2023393410A1/en active Pending
- 2023-12-15 TW TW112148944A patent/TWI922868B/zh active
- 2023-12-15 IL IL321433A patent/IL321433A/en unknown
- 2023-12-15 KR KR1020257023582A patent/KR20250121114A/ko active Pending
- 2023-12-15 CN CN202380085626.4A patent/CN120359223A/zh active Pending
- 2023-12-15 US US18/541,006 patent/US20240247001A1/en active Pending
- 2023-12-15 EP EP23836591.0A patent/EP4634186A1/en active Pending
- 2023-12-15 PE PE2025001219A patent/PE20251925A1/es unknown
-
2025
- 2025-01-27 US US19/038,077 patent/US12441744B2/en active Active
- 2025-06-11 CL CL2025001706A patent/CL2025001706A1/es unknown
- 2025-06-12 DO DO2025000143A patent/DOP2025000143A/es unknown
- 2025-06-12 MX MX2025006884A patent/MX2025006884A/es unknown
- 2025-07-16 CO CONC2025/0009649A patent/CO2025009649A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4634186A1 (en) | 2025-10-22 |
| WO2024127350A1 (en) | 2024-06-20 |
| TWI922868B (zh) | 2026-04-21 |
| KR20250121114A (ko) | 2025-08-11 |
| US20240247001A1 (en) | 2024-07-25 |
| JP2026500305A (ja) | 2026-01-06 |
| PE20251925A1 (es) | 2025-08-05 |
| CN120359223A (zh) | 2025-07-22 |
| US12441744B2 (en) | 2025-10-14 |
| MX2025006884A (es) | 2025-07-01 |
| UY40564A (es) | 2024-06-28 |
| IL321433A (en) | 2025-08-01 |
| CO2025009649A2 (es) | 2025-08-08 |
| TW202440578A (zh) | 2024-10-16 |
| CR20250283A (es) | 2025-08-21 |
| CL2025001706A1 (es) | 2025-08-18 |
| US20250197425A1 (en) | 2025-06-19 |
| DOP2025000143A (es) | 2025-08-15 |
| AU2023393410A1 (en) | 2025-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40564A (es) | Purinas 2,6,9-trisustituidas | |
| CO2021007230A2 (es) | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) | |
| MX2021014096A (es) | Compuestos heterociclicos, metodos de preparacion y usos de estos. | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| BR112019012217A2 (pt) | compostos de amino-triazolopiridina e seu uso no tratamento de câncer | |
| BRPI0408068A (pt) | derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| CY1116281T1 (el) | Ιμιδαζο[4,5-c]κινολινες ως αναστολεις dna-pk | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| CO5700751A2 (es) | Derivados de 4-(6-cloro-2,3-metilendioxianilino)-7 (alcoxi sustituiidos)-5-tetrahidropiran-4-iloxiquinazolina como inhibidores de la enzima tirosina quinasa no receptora y composiciones que los contienen | |
| UY27742A1 (es) | Derivados de quinazolina | |
| MX2017000806A (es) | Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos. | |
| UY32059A (es) | Compuestos de pirrolo [2,3-d] pirimidina | |
| CR9663A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| AR072622A1 (es) | Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas | |
| AR059320A1 (es) | Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico | |
| MX2025001108A (es) | Inhibidores de cinasas aminoheteroarílicos. | |
| UY27452A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer | |
| BR112022022452A2 (pt) | Inibidores de il4i1 e métodos de uso | |
| BR112023005005A2 (pt) | Inibidores não covalentes da cinase 7 dependente de ciclina (cdk7) | |
| MX2024010321A (es) | Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
| AR128842A1 (es) | Pirimidinas para degradar la tirosina quinasa de bruton | |
| DOP2025000197A (es) | Inhibidores de quinasa dependientes de ciclina (cdk2) | |
| BR112022001158A2 (pt) | Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina |